

Kevin E Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3146503/publications.pdf>

Version: 2024-02-01

23
papers

6,422
citations

430874

18
h-index

610901

24
g-index

33
all docs

33
docs citations

33
times ranked

8545
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021, 385, 585-594.	27.0	2,411
2	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine, 2022, 386, 1532-1546.	27.0	1,709
3	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ, The, 2021, 373, n1088.	6.0	881
4	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. New England Journal of Medicine, 2022, 386, 340-350.	27.0	501
5	Extended interval BNT162b2 vaccination enhances peak antibody generation. Npj Vaccines, 2022, 7, 14.	6.0	101
6	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nature Communications, 2021, 12, 7217.	12.8	80
7	High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. EClinicalMedicine, 2020, 28, 100597.	7.1	65
8	Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. Journal of Infection, 2021, 82, 162-169.	3.3	61
9	Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. The Lancet Healthy Longevity, 2021, 2, e811-e819.	4.6	54
10	Disease severity during SARS-COV-2 reinfection: a nationwide study. Journal of Infection, 2022, 84, 542-550.	3.3	49
11	Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March~June 2021, England. Eurosurveillance, 2021, 26, .	7.0	47
12	Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nature Microbiology, 2022, 7, 1180-1188.	13.3	39
13	VITT and Second Doses of Covid-19 Vaccine. New England Journal of Medicine, 2022, 386, 95-95.	27.0	38
14	Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. Journal of Infection, 2021, 83, 483-489.	3.3	37
15	Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. Journal of Infection, 2020, 81, 785-792.	3.3	36
16	Robust antibody responses in 70~80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Eurosurveillance, 2021, 26, .	7.0	34
17	Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5~6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. The Lancet Healthy Longevity, 2021, 2, e554-e560.	4.6	34
18	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. ELife, 2021, 10, .	6.0	28

#	ARTICLE	IF	CITATIONS
19	Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England. <i>Journal of Infection</i> , 2022, 84, 692-700.	3.3	13
20	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. <i>Eurosurveillance</i> , 2021, 26, .	7.0	10
21	Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. <i>Journal of Infection</i> , 2022, 84, 814-824.	3.3	8
22	Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. <i>Epidemiology and Infection</i> , 2022, 150, .	2.1	8
23	Effectiveness of oral aciclovir in preventing maternal chickenpox: A comparison with VZIG. <i>Journal of Infection</i> , 2022, , .	3.3	2